Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Published:
Last Updated:
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.
Published:
Last Updated:
Tthe top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, American Express, American Water Works, Celgene and Square.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
Published:
Last Updated:
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Published:
Last Updated:
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now at...
Published:
Last Updated:
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Last Updated:
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
Published:
Last Updated:
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Published:
Last Updated:
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Published:
Last Updated:
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Published:
Last Updated: